PPA-2021-0023 - Remdesivir Overview

By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several
vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19.
Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but
one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a
reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical
evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We
found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved
14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the
reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.